[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2486675T3 - Análogo de péptido de oxintomodulina - Google Patents

Análogo de péptido de oxintomodulina Download PDF

Info

Publication number
ES2486675T3
ES2486675T3 ES10801033.1T ES10801033T ES2486675T3 ES 2486675 T3 ES2486675 T3 ES 2486675T3 ES 10801033 T ES10801033 T ES 10801033T ES 2486675 T3 ES2486675 T3 ES 2486675T3
Authority
ES
Spain
Prior art keywords
peptide analog
cys
oxintomodulin peptide
oxintomodulin
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10801033.1T
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Wayne David Kohn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43587001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2486675(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2486675T3 publication Critical patent/ES2486675T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un análogo de péptido de oxintomodulina que comprende la secuencia de amino ácidos:**Fórmula** en la que Xaa38 es Cys, Cys-PEG o se encuentra ausente; Xaa39 es Cys, Cys-PEG o se encuentra ausente; y en la que el amino ácido C-terminal está opcionalmente amidado.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15

Claims (1)

  1. imagen1
    imagen2
ES10801033.1T 2009-12-22 2010-12-15 Análogo de péptido de oxintomodulina Active ES2486675T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28888809P 2009-12-22 2009-12-22
US288888P 2009-12-22
US35257610P 2010-06-08 2010-06-08
US352576P 2010-06-08
PCT/US2010/060390 WO2011087672A1 (en) 2009-12-22 2010-12-15 Oxyntomodulin peptide analogue

Publications (1)

Publication Number Publication Date
ES2486675T3 true ES2486675T3 (es) 2014-08-19

Family

ID=43587001

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10801033.1T Active ES2486675T3 (es) 2009-12-22 2010-12-15 Análogo de péptido de oxintomodulina

Country Status (34)

Country Link
US (1) US8367607B2 (es)
EP (1) EP2515928B1 (es)
JP (1) JP5717759B2 (es)
KR (1) KR101399671B1 (es)
CN (1) CN102740873B (es)
AR (1) AR079345A1 (es)
AU (1) AU2010341651B2 (es)
BR (1) BR112012017348B1 (es)
CA (1) CA2784671C (es)
CL (1) CL2012001686A1 (es)
CO (1) CO6551738A2 (es)
CR (1) CR20120338A (es)
DK (1) DK2515928T3 (es)
DO (1) DOP2012000176A (es)
EA (1) EA022820B1 (es)
ES (1) ES2486675T3 (es)
HK (1) HK1170941A1 (es)
HN (1) HN2012001321A (es)
HR (1) HRP20140616T1 (es)
IL (1) IL220161B (es)
JO (1) JO2976B1 (es)
MA (1) MA33825B1 (es)
MX (1) MX2012007438A (es)
MY (1) MY160773A (es)
NZ (1) NZ600731A (es)
PE (1) PE20121393A1 (es)
PL (1) PL2515928T3 (es)
PT (1) PT2515928E (es)
RS (1) RS53505B1 (es)
SG (1) SG181430A1 (es)
SI (1) SI2515928T1 (es)
TN (1) TN2012000302A1 (es)
TW (1) TWI423812B (es)
WO (1) WO2011087672A1 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8052996B2 (en) 2005-02-03 2011-11-08 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
WO2007056362A2 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
IL290847B2 (en) 2007-04-23 2024-11-01 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and their uses
JP5669582B2 (ja) 2007-10-30 2015-02-12 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴンアンタゴニスト
EP2214691B1 (en) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010011439A2 (en) 2008-06-17 2010-01-28 Indiana University Research And Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
RU2753280C2 (ru) 2009-09-28 2021-08-12 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US8551946B2 (en) 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
JP6121323B2 (ja) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
ES2875748T3 (es) 2011-06-10 2021-11-11 Hanmi Science Co Ltd Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de la obesidad que los comprende
RS58606B1 (sr) 2011-06-17 2019-05-31 Hanmi Science Co Ltd Konjugat koji sadrži oksintomodulin i imunoglobulinski fragment, i njegova upotreba
JP6184404B2 (ja) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
ME02816B (me) 2011-06-22 2018-01-20 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
CN103957927B (zh) 2011-11-17 2016-11-09 印第安纳大学研究及科技有限公司 呈现糖皮质激素受体活性的胰高血糖素超家族肽
PE20142405A1 (es) 2012-04-19 2015-01-25 Opko Biolog Ltd Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas
IN2015DN00003A (es) 2012-06-04 2015-05-22 Opko Biolog Ltd
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
EP2916819B1 (en) 2012-11-06 2019-07-10 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
PT2922867T (pt) 2012-11-20 2021-10-29 Opko Biologics Ltd Método de aumentar o volume hidrodinâmico de polipéptidos anexando péptidos carboxi terminais de gonadotrofina
SG11201504215PA (en) 2012-12-21 2015-06-29 Sanofi Sa Functionalized exendin-4 derivatives
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
CN107920884B (zh) 2015-06-03 2021-08-27 因塔西亚制药公司 植入物放置和移除系统
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
KR102473014B1 (ko) 2015-06-19 2022-11-30 옵코 바이오로직스 리미티드 장기-작용성 응고 인자 및 그의 제조 방법
TWI783244B (zh) 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2017212494A1 (en) 2016-06-09 2017-12-14 Opko Biologics Ltd. Long-acting oxyntomodulin formulation and methods of producing and administering same
IL264208B1 (en) 2016-07-11 2024-10-01 Opko Biologics Ltd Long-term coagulation factors and methods for their preparation
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
CN108299553B (zh) * 2017-01-13 2021-07-16 博瑞生物医药（苏州）股份有限公司 胃泌酸调节素修饰物
KR101990075B1 (ko) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
WO2020017916A1 (en) 2018-07-19 2020-01-23 D&D Pharmatech Inc. Pharmaceutical composition comprising polypeptide
US20200262887A1 (en) * 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445090A (en) 1991-07-25 1995-08-29 Mim Industries, Inc. Interchangeable clamp for use in a sewing machine
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
WO1996014336A1 (fr) * 1994-11-07 1996-05-17 Kyowa Hakko Kogyo Co., Ltd. Nouvelle oxyntomoduline
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6362254B2 (en) 1998-03-12 2002-03-26 Shearwater Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
WO2001046291A1 (en) 1999-12-22 2001-06-28 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
NZ541534A (en) 2003-03-19 2008-05-30 Lilly Co Eli Polyethelene glycol link glp-1 compounds
CN101166545B (zh) 2005-05-13 2011-06-15 伊莱利利公司 Glp-1聚乙二醇化的化合物
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
KR101349808B1 (ko) 2005-06-13 2014-02-13 임페리얼 이노베이션스 리미티드 섭취행동에 관한 신규 화합물들 및 이들의 효능
WO2007056362A2 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
CA2638800A1 (en) * 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
WO2009030771A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
AR079344A1 (es) * 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad

Also Published As

Publication number Publication date
DOP2012000176A (es) 2012-08-31
HRP20140616T1 (hr) 2014-08-15
TWI423812B (zh) 2014-01-21
TN2012000302A1 (en) 2013-12-12
US20110152182A1 (en) 2011-06-23
JP5717759B2 (ja) 2015-05-13
CA2784671A1 (en) 2011-07-21
CO6551738A2 (es) 2012-10-31
DK2515928T3 (da) 2014-08-25
HN2012001321A (es) 2015-08-31
WO2011087672A1 (en) 2011-07-21
MA33825B1 (fr) 2012-12-03
PE20121393A1 (es) 2012-10-26
PL2515928T3 (pl) 2014-11-28
JP2013515057A (ja) 2013-05-02
RS53505B1 (en) 2015-02-27
US8367607B2 (en) 2013-02-05
EP2515928B1 (en) 2014-06-18
CN102740873A (zh) 2012-10-17
JO2976B1 (en) 2016-03-15
MY160773A (en) 2017-03-15
SG181430A1 (en) 2012-07-30
SI2515928T1 (sl) 2014-08-29
HK1170941A1 (en) 2013-03-15
TW201143793A (en) 2011-12-16
IL220161B (en) 2018-12-31
BR112012017348B1 (pt) 2019-11-05
AU2010341651A1 (en) 2012-06-07
NZ600731A (en) 2014-06-27
CN102740873B (zh) 2014-11-05
AR079345A1 (es) 2012-01-18
PT2515928E (pt) 2014-09-03
AU2010341651B2 (en) 2014-01-16
IL220161A0 (en) 2012-07-31
KR20120096022A (ko) 2012-08-29
EA201290549A1 (ru) 2013-01-30
EP2515928A1 (en) 2012-10-31
CL2012001686A1 (es) 2012-11-23
MX2012007438A (es) 2012-07-17
KR101399671B1 (ko) 2014-05-27
BR112012017348A2 (pt) 2017-01-10
CR20120338A (es) 2012-07-23
EA022820B1 (ru) 2016-03-31
CA2784671C (en) 2015-06-16

Similar Documents

Publication Publication Date Title
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2528346T3 (es) Derivado de péptido insulinotrópico en el que se ha modificado su aminoácido N-terminal
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2652643T3 (es) Péptidos terapéuticos y su uso contra la corea de Huntington
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
ES2513392T3 (es) Materiales biológicos y usos de los mismos
ES2527242T3 (es) Composiciones que comprenden un germinante y un agente antimicrobiano
UA118167C2 (uk) Пептид та його застосування
ES2666720T3 (es) Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
BRPI0819092A2 (pt) Evolução direcionada usando proteínas que compreendem aminoácidos não naturais.
ES2527454T3 (es) El uso de derivados del péptido Wnt5-a para el tratamiento de melanoma y cáncer gástrico
DE602005008996D1 (de) Radiofluorierte peptide
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
ES2616017T3 (es) Composiciones que contienen sulfato de condroitina, nattocinasa y compuestos de sulfhidrilo para su uso en el tratamiento de inflamación
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
AR083126A1 (es) Composicion vacunal para el control de las infestaciones por ectoparasitos
EA201290541A1 (ru) Модифицированные бычьи соматотропиновые полипептиды и их применение
PE20150198A1 (es) Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montana por falta de oxigeno y presion de aire reducida
CL2009000665A1 (es) Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas.
DK2207790T3 (da) Biologisk aktive C-terminalt argininholdige peptider